| Diabetes Decisions and Controversies: Glucose Management or Pathophysiology? |
 |
||||||||||||||||||||||||||
| CME Web Archive | ||||||||||||||||||||||||||
|
Availability Date: September 28, 2009 |
||||||||||||||||||||||||||
| Diabetes Decisions and Controversies: Glucose Management or Pathophysiology? Release Date: September 28, 2009 Expiration Date: September 28, 2010
Target Audience This activity has been designed to meet the educational needs of healthcare professionals involved in the care of patients with diabetes. Program Overview Diabetes is a serious, progressive disease that exposes patients to increased risks for serious microvascular and neurological complications, and current data suggest that: 1) patients with diabetes have lost the majority of their β-cell function and are at increased risk for microvascular complications at the time of diagnosis, and 2) despite being on treatment, many of these patients are at continued risk because of inadequate glycemic control. These facts, in addition to the availability of new pharmacological therapies, demand medical education aimed at illustrating the significance of targeting the pathophysiology of diabetes rather than just A1C values to preserve β-cell function and improve postprandial and overall glycemic control for patients with diabetes. Clinicians are unmistakably aware of the barriers to achieving optimal outcomes for the rapidly expanding population of patients with diabetes, and as many as 40% are calling for education, according to the International Diabetes Federation.1 This activity will consist of a 1-hour live presentation by Dr. DeFronzo, a leading faculty in the area of diabetes management, with a focus on the controversial benefits and trade-offs between a pathophysiologic approach and a glucose management approach to managing diabetes. The program will focus on the potential decisions that confront healthcare professionals when considering whether to just manage patients’ glucose levels or whether to consider other physiologic factors like b-cell function and weight in addition to glucose management. The program will include an overview of the pathophysiology of diabetes and specific case-based situations to enhance application-based learning. The program will conclude with an interactive question and answer session. Reference
Educational Objectives After completing this activity, the participant should be better able to:
Ralph Anthony DeFronzo, MD Professor of Medicine and Chief, Diabetes Division University of Texas Health Science Center Audie L. Murphy Memorial Veterans Affairs Hospital Deputy Director, Texas Diabetes Institute San Antonio, Texas Accreditation Statement This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and ACCELMED. PIM is accredited by the ACCME to provide continuing medical education for physicians. Credit Designation Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Disclosure of Conflicts of Interest Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest. Method of Participation There are no fees for participating and receiving CME credit for this activity. During the period June 8, 2009 through November 8, 2009, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the posttest by recording the best answer to each question in the answer key on the evaluation form; 4) complete the evaluation form; and 5) mail or fax the evaluation form with answer key to Postgraduate Institute for Medicine. A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. Your statement of credit will be mailed to you within 3 weeks. MediaOnline AudioWeb Archive Disclosure of Unlabeled Use This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), ACCELMED, Amylin Pharmaceuticals, Inc. and Lilly USA, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, ACCELMED, Amylin Pharmaceuticals, Inc. and Lilly USA, LLC. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. |
||||||||||||||||||||||||||
| ACCELMED Home Page | ACCELMED Programs | About Us | Contact Us |